Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Change-In-Working-Capital" stands at 0.015 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 12/31/2023.
Novartis AG's third quarter result of 1.34 Billion USD for the item "Change In Working Capital" represents an increase of 202.26 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 1.34 Billion USD for the item "Change In Working Capital" represents an increase of 28.46 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 0.015 Billion USD for the item "Change In Working Capital" represents an increase of 105.34 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 1.49 Billion United States Dollars compared to the value the year prior.
The 1 year change is 1.49 Billion United States Dollars.
The 3 year change is 1.58 Billion United States Dollars.
The 5 year change is 1.49 Billion United States Dollars.
The 10 year change is 2.16 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Change In Working Capital | 905,699,262,464.00 |
![]() | Johnson & Johnson - Change In Working Capital | 486,508,953,600.00 |
![]() | AbbVie Inc - Change In Working Capital | 399,570,305,024.00 |
![]() | Roche Holding AG - Change In Working Capital | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Change In Working Capital | 280,205,508,085.11 |